News | April 11, 2013

Society of Nuclear Medicine Celebrates 60th Annual Meeting

Meeting highlights nuclear medicine and molecular imaging advances from bench to bedside

April 11, 2013 — An estimated 5,000 nuclear medicine and molecular imaging professionals are expected to gather in June for the 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) to discuss the latest advances in radiotracers, imaging modalities, radionuclide therapies and quality.

The meeting will be held June 8-12 in Vancouver, British Columbia, Canada. This year’s meeting marks the 60th anniversary of the SNMMI Annual Meeting.

“Our first meeting was held in Seattle, Wash., in 1954, and was reported to have had 109 attendees who heard 13 scientific presentations and one panel discussion,” said Peter Herscovitch, M.D., chair of SNM’s Scientific Program Committee (SPC).  

Today, the SNMMI Annual Meeting offers education opportunities for physicians, technologists, pharmacists, physicists, scientists and laboratory professionals in the nuclear medicine and molecular imaging fields. More than 110 expert-led continuing education sessions will be held on topics including emerging PET radiotracers, dementia, neuroendocrine tumor imaging, novel targeted radiopharmaceutical therapies and hybrid imaging. Several other special courses will be held, including 11 categorical sessions, 22 self-assessment modules, a two-day CT case review workshop and a new Education Forum designed specifically for nuclear medicine program directors. The Annual Meeting will also feature a special session honoring Henry N. Wagner, Jr., M.D., nuclear medicine pioneer and visionary, who died last year.

SNMMI will again offer its Virtual Meeting for those who missed sessions of interest at the meeting or those unable to travel to Vancouver. The Virtual Meeting will include 70 of the most popular sessions, captured on video and available to view online or on a mobile device.

For more information: www.snmmi.org/am2013

Related Content

SpaceOAR Hydrogel Now Available in Japan
News | Patient Positioning Radiation Therapy | July 16, 2018
Augmenix K.K. announced that SpaceOAR hydrogel, a soft, implanted absorbable gel spacer is now available to all...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
RaySearch Releases New Version of RayCare OIS
Technology | Oncology Information Management Systems (OIMS) | July 13, 2018
RaySearch has released RayCare 2A, the latest version of its flagship oncology information system (OIS). RayCare is...
Lack of Insurance Coverage Delaying Proton Therapy Clinical Trials
News | Proton Therapy | July 12, 2018
Randomized clinical trials are the gold standard of cancer research and can shed light on whether innovative, new...
Bruce Power Joins Forces With ITM to Supply Lutetium-177 for Cancer Therapy
News | Radiation Therapy | July 11, 2018
Canadian nuclear power company Bruce Power and German-based Isotope Technologies Garching (ITG) signed an agreement to...
MedStar Georgetown University Hospital Now Clinical With RayStation and Hyperscan
News | Treatment Planning | July 05, 2018
MedStar Georgetown University Hospital in Washington D.C., has begun patient treatments using the RayStation treatment...
Northern Centre for Cancer Care (NCCC)

Northern Centre for Cancer Care (NCCC).

Sponsored Content | Case Study | Radiation Therapy | July 05, 2018
Established in 2009, Northern Centre for Cancer Care (NCCC) is the largest center of its kind in the north of England....
Researcher Investigates Eliminating Radiation for HER2-Positive Breast Cancer
News | Radiation Therapy | July 02, 2018
Researchers at The University of Kansas Cancer Center have launched a clinical trial that eliminates radiation from the...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
Overlay Init